Evidence map›Paper›PMID 38473247›Full record

ArticleCancers2024

Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer.

Vahé Barsegian, Daniel Möckel, Sebastian Buehler, Stefan P Müller, Michael C Kreissl, Patrick Ostheim, Peter A Horn, Monika Lindemann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Vahé BarsegianInstitute of Nuclear Medicine, Helios Kliniken, 19055 Schwerin, Germany.
Daniel MöckelInstitute of Nuclear Medicine, Helios Kliniken, 19055 Schwerin, Germany.
Sebastian BuehlerInstitute of Nuclear Medicine, Helios Kliniken, 19055 Schwerin, Germany.
Stefan P MüllerDepartment of Nuclear Medicine, University Hospital, 45147 Essen, Germany.
Michael C KreisslDivision of Nuclear Medicine, Department of Radiology and Nuclear Medicine, Otto von Guericke University, 39106 Magdeburg, Germany.ORCID 0000-0001-5905-6015
Patrick OstheimBundeswehr Institute of Radiobiology, 80937 Munich, Germany.
Peter A HornInstitute for Transfusion Medicine, University Hospital, 19055 Essen, Germany.
Monika LindemannInstitute for Transfusion Medicine, University Hospital, 19055 Essen, Germany.ORCID 0000-0001-6708-4390
Helios Kliniken · DEEssen University Hospital · DEInstitut für Radiobiologie der BundeswehrOtto-von-Guericke-Universität Magdeburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous data indicate that one cycle of treatment with radium-223 (

Indexed as

antimicrobial immune responseELISpotinterferon-γinterleukin-10lymphocyte proliferationprediction of tumor burdenradium-223 therapy

Identifiers

PMID38473247
PMCPMC10930607
OpenAlexW4392101802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.